Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
Evolving Treatment Landscape in Relapsed/Refractory Multiple Myeloma: MonumenTAL-1 and RedirecTT-1
June 19th 2023Key opinion leaders review recent data from the ASCO 2023 annual meeting surrounding the MonumenTAL-1 and RedirecTT-1 trials, considering their impact on the real-world management of relapsed/refractory multiple myeloma.
Amivantamab vs Alternative Therapies in Patients with EGFR Exon 20–Mutated NSCLC
April 7th 2023Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss the evolving treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations and results from a real-world study that may impact the field.
Utility of ctDNA to Manage Adjuvant Therapy in CRC Based on Results of the GALAXY Study
May 5th 2022Stacy A. Cohen, MD, and Mark Lewis, MD review results from the GALAXY study on circulating tumor DNA dynamics in CRC that were recently presented at ASCO GI 2022, and discuss the clinical implications of the findings.
Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
March 4th 2022Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.
Routine Clinical Practice Comparison of IRD and Rd in RR Multiple Myeloma
January 19th 2022Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Clinical Practice Experience with Avelumab First-Line Maintenance in Urothelial Carcinoma
December 22nd 2021Daniel Petrylak, MD and Donald Barry Boyd, MD, MS review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.
18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence
December 22nd 2021Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.